Avadel Pharmaceuticals PLC
NASDAQ:AVDL
Avadel Pharmaceuticals PLC
Revenue
Avadel Pharmaceuticals PLC
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
Revenue
$169.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
23%
|
CAGR 10-Years
27%
|
|
|
Perrigo Company PLC
NYSE:PRGO
|
Revenue
$4.4B
|
CAGR 3-Years
2%
|
CAGR 5-Years
2%
|
CAGR 10-Years
0%
|
|
|
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
|
Revenue
$4.1B
|
CAGR 3-Years
10%
|
CAGR 5-Years
13%
|
CAGR 10-Years
13%
|
|
|
Iterum Therapeutics PLC
NASDAQ:ITRM
|
Revenue
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
G
|
GH Research PLC
NASDAQ:GHRS
|
Revenue
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Cosmo Pharmaceuticals NV
SIX:COPN
|
Revenue
€185.4m
|
CAGR 3-Years
43%
|
CAGR 5-Years
30%
|
CAGR 10-Years
10%
|
|
Avadel Pharmaceuticals PLC
Revenue Breakdown
Breakdown by Geography
Avadel Pharmaceuticals PLC
Breakdown by Segments
Avadel Pharmaceuticals PLC
|
Total Revenue:
169.1m
USD
|
|
Reportable Segment:
169.1m
USD
|
Avadel Pharmaceuticals PLC
Glance View
Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. The company is headquartered in Dublin, Dublin and currently employs 66 full-time employees. The Company’s lead product candidate, FT218, is an investigational once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness (EDS), and cataplexy in narcolepsy patients. Its Micropump allows for the development of modified and/or controlled release solid, oral dosage formulations of drugs. Its LiquiTime technology allows for development of modified/controlled release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its Medusa technology allows for the development of extended-/modified-release injectable dosage formulations of drugs.
See Also
What is Avadel Pharmaceuticals PLC's Revenue?
Revenue
169.1m
USD
Based on the financial report for Dec 31, 2024, Avadel Pharmaceuticals PLC's Revenue amounts to 169.1m USD.
What is Avadel Pharmaceuticals PLC's Revenue growth rate?
Revenue CAGR 10Y
27%
Over the last year, the Revenue growth was 505%.
You don't have any saved screeners yet